Vor Biopharma VOR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Liquidity | |||||
| Current ratio | 18.2×+13.0× | 5.2×-3.9× | 9×-9.0× | 18.1×-3.1× | |
| Quick ratio | 18.2×+13.0× | 5.2×-3.9× | 9×-9.0× | 18.1×-3.1× | |
| Cash ratio | 15.8×+11.3× | 4.4×+2.4× | 2×-2.4× | 4.4×-7.4× | |
| Leverage | |||||
| Debt-to-assets | 0×-0.2× | 0.2×0.0× | 0.2×0.0× | 0.1×+0.1× | |
| Per Share | |||||
| Book value per share | -$16.64+40.8% | -$28.14-1,354% | $2.24-64.6% | $6.34-2.0% | |
| Valuation | |||||
| Market capitalization | $784.61M+2,594% | $138.24M-9.5% | $152.76M-50.6% | $309.21M-28.6% | |
| Enterprise value | $617.68M+5,866% | $88.13M-43.9% | $157.06M-45.9% | $290.42M-12.4% | |
| Free cash flow yield | -18.6%+316pp | -72.3%-5.9pp | -66.4%-36.1pp | -30.3%-13.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vor Biopharma's ratios come from?
- Every ratio is computed from Vor Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.